Diabetes Obes Metab: Glucose-Sodium Conjoined 2 Inhibitors for Ischemic Heart Disease

A recent study in the journal Diabetes Obesity and Metabolism, an authoritative journal for metabolic endocrine diseases, compared cardiovascular risk between users and non-users of SGLT2 inhibitors based on electronic medical records from a large integrated healthcare system in Southern Louisianaresearchers obtained demographic, anthrocometric, laboratory tests, and drug prescription information from the subjects' electronic health records, using SGLT2 inhibitors as initial or additional treatmentsThrough the mediated analysis, the researchers demonstrated the relationship between the use of SGLT2 inhibitors and changes in metabolic risk factors and the risk of ischemic heart diseasethe study included 5,338 patients who were newly used with SGLT2 inhibitors and matched 13,821 patients who did not use SGLT2 inhibitorsIn follow-up for an average of 3.26 years, 2,302 patients had ischemic heart diseaseAfter adjusting for a variety of confounding factors, patients using SGLT2 inhibitors had a lower risk of developing ischemic heart disease (0.63 risk ratio compared to HR; 0.54-0.73 ci)Patients with SGLT2 inhibitors were 6 months (HR 0.36; 95% CI 0.25-0.44), 12 months (HR 0.40; 95% CI 0.32-0.49), 24 The risk of ischemic heart disease was also low for months (0.53; 95% CI 0.43-0.60) and 36 months (HR 0.65; 95% CI 0.54-0.73)Reducing systolic pressure partially mediated SGLT2 inhibitors to reduce the risk of ischemic heart disease in patientsevidence from real-world data suggests that SGLT2 inhibitors reduce the risk of ischemic heart disease, which has benefits beyond blood sugar